california semaglutide weight loss Program in Newport Beach, CA | Arogya Med Care GLP-1 Weight Loss Injections: Semaglutide

Switching from one GLP-1 receptor agonist, like Semaglutide or Tirzepatide , to another requires careful planning to maintain the benefits of treatment while minimizing potential side effects especially those affecting the gastrointestinal system

In the diabetes TRIUMPH-2 trial, reported side effects included: Diarrhea (around 27 to 34 percent of participants, depending on the dose) Nausea (14 to 28 percent) Constipation (14 to 17 percent) Decreased appetite (6 to 17 percent) Vomiting (6 to 16 percent) In the TRIUMPH-3 trial for adults with severe obesity and heart disease, participants reported: Diarrhea (around 24 to 30 percent of participants, depending on the dose) Nausea (22 percent) Constipation (16 to 18 percent) Decreased appetite (14 to 15 percent) Hyperglycemia, or high blood sugar (3 to 4 percent) The high rates of diarrhea surprised Ali

The Bottom Line Many people successfully manage heartburn and reflux symptoms while continuing their GLP-1 therapy

The Key Risk: Euglycemic DKA One of the most serious concerns with GLP-1 use in Type 1 diabetes is euglycemic DKA a form of diabetic ketoacidosis where blood glucose may not be severely elevated